MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 November 2020
Melanoma Institute Australia is proud to announce that MIA’s Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer, as well as MIA Faculty member Associate Professor Alex Menzies and former Faculty member Professor Rick Kefford AM, have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe. It identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.
Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.
According to Clarivate, 6,167 researchers from more than 60 countries and regions have been recognized this year, with Australian research institutes continuing to punch above their weight. In a country of just 25 million, the number of Australian researchers recognized in 2020 is 305.
MIA Co-Medical Director Professor Georgina Long AO, whose video interview with Clarivate is featured online, said:
“This accolade is recognition of the ground-breaking work being carried out by the entire team at Melanoma Institute Australia as we continue our quest to develop treatments that will ultimately save the lives of all melanoma patients.”
Fellow Co-Medical Director of MIA Professor Richard Scolyer said:
“It is an honour to again be included on this list alongside several other MIA researchers and clinicians. It shows the phenomenal and ongoing impact that MIA’s work and research is having around the world.”
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate said:
“In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers from Melanoma Institute Australia who are having a great impact on the research community as measured by the rate at which their work is being cited by others.”
Melanoma Institute Australia is affiliated with The University of Sydney
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).